Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma
| Autor: | Umesh T. Sankpal, Ishna Sharma, Riyaz Basha, Kalyani Narra, Bassam Ghabach, Swathi Sridhar, Latha Neerukonda |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Sorafenib
Oncology Cancer Research medicine.medical_specialty Carcinoma Hepatocellular medicine.medical_treatment chemistry.chemical_compound Internal medicine Targeted Molecular Therapy Humans Medicine Molecular Targeted Therapy Hepatitis Clinical Trials as Topic Chemotherapy business.industry Phenylurea Compounds Liver Neoplasms Cancer medicine.disease chemistry Hepatocellular carcinoma Quinolines business Lenvatinib Liver cancer Signal Transduction medicine.drug |
| Zdroj: | Critical Reviews™ in Oncogenesis. 25:47-55 |
| ISSN: | 0893-9675 |
| Popis: | Liver cancer is the 6th leading cause of cancer related deaths in the US even though it ranks 14th in incidence. More men are diagnosed with liver cancer than women, and the number of projected deaths among men (20,020) is almost double that among women (10,140) in the US. Infections like hepatitis and metabolic conditions like obesity are believed to be major risk factors for the onset of liver cancer. Hepatocellular carcinoma (HCC), the most common type of liver cancer, accounts for 75% of all cases. Chemotherapy has not been effective in treating HCC. Targeted therapies are being used in advanced HCC patients due to a better survival and less side effects when compared to traditional chemotherapy. Therapeutic agents targeting the regulators of growth factor signaling pathways and the mediators of downstream signaling-for example, inhibitors of the tyrosine kinase receptor-are used as targeted molecular therapies. Kinase inhibitors that modulate growth signals, such as sorafenib and lenvatinib, are commonly employed in targeted molecular therapy for HCC patients. This review covers these agents, highlighting modes of action and providing details on clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|